Oxford, UK – May 8, 2025 — OrganOx Ltd. has completed the second closing of a $160 million private financing round, bringing in new strategic investors Intuitive Ventures and Terumo Ventures. The investment will support the company’s continued expansion of its metra® perfusion technology, which aims to improve transplant outcomes and organ availability globally.
Technology Overview: The metra® Platform
OrganOx’s metra® platform is a normothermic machine perfusion (NMP) system that maintains donor livers in a metabolically active state outside the body. This approach enables real-time functional assessment of organs prior to transplantation and extends preservation times, offering a significant improvement over traditional cold storage methods. The technology has already supported over 5,000 liver transplants across the U.S., Europe, Canada, and Australia.
Strategic Use of Funds and Clinical Pipeline
Proceeds from the financing will accelerate the commercial scale-up of the metra® liver platform and advance development of a similar solution for kidney transplants. OrganOx is also exploring new frontiers in organ support, having recently received FDA clearance—alongside its partner eGenesis—for a first-in-human clinical study involving genetically engineered porcine livers for patients with acute-on-chronic liver failure.
Strategic Investment and Industry Alignment
The addition of Intuitive Ventures and Terumo Ventures brings not only capital but also strategic insight from investors with deep experience in surgical technologies and global healthcare markets.
OrganOx Executive Chairman Dr. Oern R. Stuge commented, “With the support of Intuitive Ventures and Terumo Ventures, we are positioned to accelerate innovation and broaden access to life-saving transplant technologies.”
Piper Sandler served as exclusive financial advisor, with legal counsel provided by Latham & Watkins LLP.
About OrganOx
OrganOx is a commercial-stage medical technology company focused on improving outcomes in organ transplantation. Spun out of the University of Oxford in 2008, OrganOx developed the metra®, a normothermic machine perfusion platform that allows donor livers to remain functional outside the body. The system enables clinicians to evaluate organ viability before transplantation and has been used in over 5,000 liver transplant procedures. OrganOx is also developing applications of its platform for kidney transplantation and novel therapeutic indications.
About Intuitive Ventures
Intuitive Ventures is the independent strategic venture capital arm of Intuitive Surgical, the pioneer in robotic-assisted surgery. With $250 million in assets under management, the firm invests globally in companies advancing minimally invasive care across diagnostics, MedTech, digital health, and therapeutics. Intuitive Ventures offers portfolio companies access to deep clinical, technical, and commercial expertise to support their growth and innovation.
About Terumo Ventures
Terumo Ventures is the corporate venture capital arm of Terumo Corporation, a global medical technology company. The fund invests in companies developing breakthrough healthcare solutions aligned with Terumo’s mission of contributing to society through healthcare. Terumo Ventures provides strategic capital and industry expertise to help early-stage innovators scale transformative medical technologies.
The Business of Biofabrication 
Leave a comment